Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Articles by Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCSeptember 23rd 2020
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCSeptember 23rd 2020
Practical Management of Early Stage HER2+ Breast CancerSeptember 23rd 2020
HER2-targeted Therapy: Routes of AdministrationSeptember 23rd 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
3
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
4
CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL
5